



AMENDMENTS TO THE CLAIMS

1.-10. (Cancel)

11. (Original) A method of modulating myocyte enlargement in a subject at risk for cardiac hypertrophy comprising the steps of administering to the subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity, wherein the effective amount modulates myocyte enlargement.

12. (Original) The method of claim 11, wherein the composition comprises a Cdk9 inhibitor.

13. (Original) The method of claim 12, wherein the Cdk9 inhibitor is flavopiridol.

14. (Original) The method of claim 11 wherein the composition comprises a compound that modulates Cdk9 activity by prohibiting the dissociation of 7SK snRNA from cyclin T1/Cdk9 complex.

15. (Original) A method of modulating cardiac hypertrophy comprising the step of administering to a subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity, wherein the effective amount modulates hypertrophic growth.

16. (Original) The method of claim 15, wherein the composition comprises a Cdk9 inhibitor.

17. (Original) The method of claim 16, wherein the Cdk9 inhibitor is flavopiridol.

18. (Original) The method of claim 15, wherein the composition comprises a compound that modulates Cdk9 activity by prohibiting the dissociation of 7SK snRNA from cyclin T/Cdk9 complex.

19. (Original) The method of claim 18, wherein the composition comprises an inhibitor of Gq.

20. (Original) The method of claim 19, wherein the Gq inhibitor is selected from the group consisting of angiotensin II inhibitors, ACE inhibitors and endothelin inhibitors.

21. (Original) The method of claim 18, wherein the composition comprises an inhibitor of calcineurin.

22. (Original) The method of claim 21, wherein the Gq inhibitor is selected from the group consisting of angiotensin II inhibitors, ACE inhibitors and endothelin inhibitors.

23. (Original) The method of claim 15, wherein the composition comprises a compound that upregulates the levels of 7SK snRNA.

24.-26. (Cancel)

27. (Original) A method of treating a subject at risk for ventricular dysfunction associated with cardiac hypertrophy comprising the steps of administering to the subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity, wherein the effective amount decreases ventricular dysfunction.

28.-34. (Cancel)